NEUP logo

NEUPHORIA THERAPEUTICS INC

NEUPNASDAQ
🏆 #4648 by market capEarnings Nov 12US Equity
$3.36▼ $0.03 (−0.88%)
🌅 Pre-market$2.96▼ 11.90%Regular close · extended-hours price shown
🔔
Track NEUP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d▼ 3.7%
14d▲ 0.3%
30d▼ 7.7%
ytd▼ 12.0%
1y▼ 27.2%
🏦Market Cap
$18M
Small Cap
📈Revenue Growth (YoY)
-92.5%
Declining
📊Gross Margin
43.5%
Healthy
💵FCF Margin
-1052118.7%
Thin
⚖️P/S Ratio
15.5x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$3.32 – $3.42
52-Week Range
$3.19 – $5.53
Volume (shares)
16,063
Avg Volume (shares)
—
Shares Outstanding
5.4M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$1M
P/E Ratio
-0.5
P/S Ratio
15.5x
EPS (TTM)
$-3.42
Dividend Yield
0.00%
Dilution (1yr)
+19.3%
NEUP logo

NEUPHORIA THERAPEUTICS INC

NEUP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −92.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
43.5%▼ −54.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▲ +768.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12.4B▼ −16095.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.4M▲ +19.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▼ −$2M YoY
StockOtter · stockotter.space

About NEUPHORIA THERAPEUTICS INC

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

PRNewsWire·Aug 4

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

GlobeNewsWire·Jul 30

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a

PRNewsWire·Jul 29

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws